Chronic Hepatitis B Treatment: When to Start, What to Expect, and How Long

Chronic hepatitis B is one of the most common serious infections in the world, and one of the quietest. An estimated 254 million people live with it, most heavily across Asia and sub-Saharan Africa, and the majority do not know. It rarely causes symptoms until the liver has already been damaged over years or decades.

This guide explains what “chronic” actually means, which tests decide whether you need medication, what the first-line antivirals do, how long treatment continues, and what monitoring looks like. It is written for patients and carers trying to understand a diagnosis, not as a substitute for the specialist managing your care.

What “chronic” hepatitis B means

Hepatitis B is a virus that infects liver cells. When an adult catches it, the immune system usually clears it within six months. Infection is called chronic when the surface antigen — HBsAg — is still detectable in the blood after six months, meaning the immune system has not cleared it and will not do so on its own.

The age at infection matters enormously. Infection acquired at birth or in early childhood becomes chronic in the great majority of cases, because an immature immune system does not mount an effective response. Infection acquired in adulthood usually resolves. This is why chronic hepatitis B is concentrated in regions where mother-to-child transmission was common before universal infant vaccination.

Why most people feel completely well

Hepatitis B does not damage the liver directly in the way a toxin would. Most of the injury comes from the immune system attacking infected liver cells. That process can run quietly for decades, producing no pain, no jaundice and no fatigue that anyone would think twice about, while scar tissue slowly accumulates.

The consequence is that feeling well tells you very little. Cirrhosis and liver cancer can develop in people who never had a symptomatic day. This is the single most important thing to understand about the disease, and the reason monitoring exists even when no medication is prescribed.

The tests that decide treatment

Four results, read together, drive almost every treatment decision.

HBsAg — hepatitis B surface antigen

The marker of active infection. Still positive after six months means chronic infection. Its eventual loss is the closest outcome to a functional cure, and it is uncommon.

HBV DNA — viral load

How much virus is circulating, reported in IU/mL. This is the number treatment is designed to drive down, and the main measure of whether treatment is working.

ALT — alanine aminotransferase

A liver enzyme that rises when liver cells are being injured. A normal ALT alongside a high viral load suggests the immune system is not currently attacking; a raised ALT with a high viral load suggests active liver injury.

HBeAg — hepatitis B e antigen

A marker associated with high viral replication. Patients are described as HBeAg-positive or HBeAg-negative, and the two groups follow different natural histories and different treatment thresholds. Losing HBeAg and developing the corresponding antibody — seroconversion — is a meaningful milestone.

Alongside these, clinicians assess how much scarring already exists, usually with elastography (a painless scan measuring liver stiffness), blood-based fibrosis scores, or occasionally a biopsy. Someone with established cirrhosis is treated on different rules from someone with a healthy liver.

Why not everyone is treated straight away

Chronic hepatitis B moves through phases, and the phase matters more than the diagnosis alone. Broadly, clinicians recognise a phase of high viral load with normal ALT and no liver injury, a phase of active immune attack with raised ALT where damage accumulates, a quieter phase with low viral load and normal enzymes, and a later HBeAg-negative phase that can reactivate after years of stability.

Medication is aimed at the phases where the liver is actually being injured. Treating someone whose immune system is not attacking their liver commits them to indefinite therapy without a clear benefit to gain. This is why a specialist may say “we will watch this” — it is a clinical position, not a delay, and it depends on repeat testing rather than a single snapshot.

Treatment is generally recommended when there is evidence of ongoing liver injury alongside significant viral replication, when there is cirrhosis at any viral load, and in specific situations such as before immunosuppressive or chemotherapy treatment, during pregnancy where the viral load is high, and where there is a family history of liver cancer. Thresholds differ between international guidelines, which is one reason two clinicians can reasonably reach different conclusions about the same patient.

The first-line medicines

Modern treatment of chronic hepatitis B rests on the nucleos(t)ide analogues. These drugs block reverse transcriptase, the enzyme HBV needs to copy its genome, and drive the viral load down — usually to undetectable levels — for as long as they are taken.

Three are considered first-line because they combine potent suppression with a high barrier to resistance:

• Entecavir — a nucleoside analogue taken once daily. Food substantially reduces its absorption, so it is prescribed on an empty stomach, at least two hours after eating and two hours before the next meal. This is the detail patients most often get wrong. Browse entecavir products or see the generic Baraclude page.
• Tenofovir disoproxil fumarate (TDF) — a nucleotide analogue taken once daily with or without food. Long-term use requires attention to kidney function and bone mineral density. See generic Viread.
• Tenofovir alafenamide (TAF) — a newer prodrug that delivers tenofovir more efficiently into liver cells, allowing a much lower dose and lower circulating drug levels. It is generally preferred where kidney or bone health is a concern. See generic Vemlidy.

Older agents — lamivudine, adefovir, telbivudine — are no longer first-line for hepatitis B. They suppress the virus but resistance emerges readily with long-term use, and once resistance develops the options narrow. Some patients started on them years ago remain on them; that is a conversation to have with a specialist rather than a change to make alone.

Pegylated interferon is a different approach entirely: a finite course, given by injection, that works by stimulating the immune response rather than blocking replication. It suits a narrow group of patients, carries a heavier side-effect burden, and is used far less often than the oral antivirals.

Choosing between entecavir and the tenofovir prodrugs depends on prior treatment history, kidney and bone status, pregnancy, HIV co-infection and cost. That comparison deserves its own discussion and is not a decision to make from an article.

What treatment does — and what it does not do

This is the part most worth being clear about. These medicines suppress the virus. They do not eliminate it.

HBV establishes a stable reservoir inside the nucleus of liver cells, in a form that current antivirals cannot reach. Suppressing circulating virus stops the immune attack, allows inflammation to settle, and in many people allows existing fibrosis to partially regress over years. It substantially reduces — but does not abolish — the risk of cirrhosis and liver cancer.

What it does not do is clear the reservoir. Stop the medication and the virus can begin replicating again, sometimes with a flare of liver inflammation that is more dangerous than the state before treatment. That is the reason treatment is normally continued indefinitely, and the reason stopping is a specialist decision rather than a personal one.

How long treatment lasts

For most people with chronic hepatitis B, the honest answer is: indefinitely, and often for life.

Guidelines do define circumstances in which stopping can be considered — typically after prolonged viral suppression in a patient without cirrhosis who meets specific serological criteria — but this is done with planned, frequent monitoring afterwards, because flares can occur months later. Anyone with established cirrhosis is generally advised to remain on treatment permanently, since a flare in a cirrhotic liver has much less margin for error.

Loss of HBsAg, sometimes called a functional cure, does occur in a small minority and can allow treatment to stop. It is a welcome outcome, not a goal that can be planned around.

Monitoring while on treatment

Treatment is not a prescription and a shrug. A typical pattern of follow-up includes:

• HBV DNA and ALT — commonly every three to six months, to confirm the virus stays suppressed and the liver stays quiet.
• Kidney function — particularly relevant on TDF, and in anyone with diabetes, hypertension or existing kidney disease.
• Liver cancer surveillance — usually an ultrasound every six months for those in a surveillance group, which includes people with cirrhosis and others stratified by age, family history and ethnicity. This continues even when the viral load is undetectable.
• Fibrosis reassessment — periodically, to track whether scarring is stable, improving or progressing.

A viral load that rises after being undetectable usually means missed doses rather than resistance, since resistance to the first-line agents is uncommon in people who have not taken older drugs before. Either way it warrants investigation rather than a silent dose change.

Adherence, and why it matters more here than elsewhere

Because these drugs suppress rather than eradicate, their benefit depends almost entirely on taking them consistently. Interruptions allow viral rebound; repeated interruptions raise the risk of selecting resistant virus and of triggering a flare.

The practical obstacles are usually mundane: running out of supply between appointments, the empty-stomach requirement for entecavir clashing with daily routine, or cost when paying out of pocket. All three are solvable, and all three are worth raising with a clinician or pharmacist rather than managing by skipping doses.

Protecting the people around you

Hepatitis B transmits through blood and body fluids, including from mother to child at birth and through sexual contact. It does not transmit through food, water, sharing utensils, hugging or coughing — a point worth stating plainly, because the social isolation that follows a diagnosis is often based on fears that are simply not accurate.

The most useful step is that household members and sexual partners are tested and, if not immune, vaccinated. The hepatitis B vaccine is safe, widely available and highly protective. In pregnancy, antiviral treatment in the third trimester where the viral load is high, combined with vaccination and immunoglobulin for the newborn, is standard practice to prevent transmission at birth.

Hepatitis B is not hepatitis C

The two are often confused because both are viral, both affect the liver and both can be chronic. They are different viruses with entirely different treatment. Hepatitis C is treated with a finite course of direct-acting antivirals — typically a few months — after which the virus is generally no longer detectable. Hepatitis B has no equivalent short course.

If you have been told you have hepatitis C rather than B, the medicines discussed here do not apply to you. You can browse our hepatitis medicines range for both conditions.

Living with the diagnosis

Chronic hepatitis B is a long-term condition that is, for most people, controllable. The combination of an effective daily tablet, regular monitoring and liver cancer surveillance changes the trajectory of the disease substantially compared with leaving it unmanaged.

What it asks in return is consistency: taking the medicine as directed, attending monitoring appointments even when you feel entirely well, keeping alcohol intake low, and staying vaccinated against hepatitis A. Used as prescribed by a licensed medical professional, these treatments are among the better-established long-term therapies in medicine.

Where to get treatment

We supply entecavir, tenofovir disoproxil fumarate and tenofovir alafenamide from licensed pharmaceutical manufacturers, alongside the wider hepatitis medicines range. A valid prescription is required, and every order is reviewed by a licensed pharmacist before dispatch. Used as prescribed by a licensed medical professional.

Frequently asked questions

Does hepatitis B treatment cure the infection?

No. The antivirals used for chronic hepatitis B suppress the virus and stop it damaging the liver, but they do not clear it from the body. The virus persists inside liver cells in a stable form that current medicines cannot reach, which is why treatment is usually long term and why stopping without specialist supervision can allow the virus to rebound.

Does everyone with chronic hepatitis B need medication?

No. Treatment decisions depend on the phase of infection, measured through HBV DNA level, ALT, HBeAg status and the amount of liver scarring. Some people are monitored for years without medication because the virus is not currently causing liver injury. That monitoring is not the same as being untreated and forgotten — it is an active plan reviewed by a specialist.

How long does hepatitis B treatment last?

For most people it is indefinite. Guidelines allow considered stopping in selected patients who meet strict criteria, but stopping carries a risk of a hepatitis flare and must be supervised by a specialist with close monitoring afterwards. Anyone with cirrhosis is generally advised to stay on treatment for life.

What is the difference between entecavir, TDF and TAF?

All three are first-line nucleos(t)ide analogues with a high barrier to resistance. Entecavir is a nucleoside analogue taken on an empty stomach. TDF (tenofovir disoproxil fumarate) and TAF (tenofovir alafenamide) are two different prodrugs of tenofovir; TAF delivers the drug more efficiently to liver cells at a lower plasma exposure, which matters most for people with kidney or bone concerns.

Can I take entecavir if I also have HIV?

Not on its own. Entecavir has activity against HIV and using it without full antiretroviral therapy can select for HIV resistance. Anyone with HIV and hepatitis B co-infection needs a combined regimen chosen by a clinician who is managing both infections together.

Do I still need liver cancer screening if my viral load is undetectable?

Yes, if you fall into a surveillance group. Suppressing the virus lowers risk but does not remove it, particularly where cirrhosis is already present or there is a family history of liver cancer. Surveillance is typically an ultrasound every six months and continues alongside treatment.

This article is general information, not medical advice. It does not replace assessment by a clinician who knows your test results and history. Treatment thresholds differ between international guidelines and individual circumstances. Always use any medicine as prescribed by a licensed medical professional.